Core Viewpoint - Viesheng Pharmaceutical-B (2561.HK) has seen a significant stock price increase, reaching a new high since December 19 of the previous year, driven by the anticipated approval of its core product, Lonapegsomatropin, which is expected to reshape the growth hormone market [1][2] Group 1: Stock Performance - Viesheng Pharmaceutical-B opened high and surged by 9.9% to HKD 38.2, marking a year-to-date increase of over 16%, outperforming the Hang Seng Index, which rose over 4% during the same period [1] Group 2: Product Development - The Insight database indicates that Lonapegsomatropin is set to exit the supplementary data task on January 12, 2026, and is expected to receive approval soon [1] - Lonapegsomatropin, a long-acting growth hormone prodrug introduced from Ascendis Pharma, is the first long-acting weekly formulation approved for pediatric growth hormone deficiency (GHD) in the U.S. and Europe [1] - The domestic growth hormone market primarily consists of daily formulations, and the introduction of a weekly formulation is anticipated to significantly enhance patient compliance and address unmet clinical needs [1] Group 3: Competitive Advantage - According to Guohai Securities, Lonapegsomatropin, based on TransCon technology, is expected to be launched soon and demonstrates superior efficacy and equivalent safety compared to short-acting growth hormones [2] - Lonapegsomatropin is the only long-acting growth hormone that continuously releases unmodified human growth hormone in the body between weekly doses, validated by completed Phase III trials in China [2] - It has shown superior efficacy and equivalent safety in positive drug control and parallel group trials compared to short-acting growth hormones [2]

Core Viewpoint - Guohai Securities reports that the long-acting growth hormone, Lonpei, based on TransCon technology, is expected to be launched soon, demonstrating superior efficacy and equivalent safety compared to short-acting growth hormones [1] Company Summary - Lonpei growth hormone was introduced by Weisheng Pharmaceutical in November 2018 through a licensing agreement with Ascendis Pharma [1] - The growth hormone utilizes TransCon (transient conjugation technology) for long-acting delivery, making it the only long-acting growth hormone that continuously releases unmodified human growth hormone between weekly doses [1] - Completed Phase III pivotal trials in China have validated that Lonpei is the only long-acting growth hormone showing superior efficacy and equivalent safety in comparison to short-acting growth hormones in positive drug control and parallel group trials [1] - Weisheng Pharmaceutical anticipates that Lonpei will receive domestic approval for marketing in the fourth quarter of 2025, suggesting that investors should closely monitor the company in the near term [1]